These findings suggest that, by studying further the role of IL-31 in sepsis, bioproducts that could lead to the blockade of IL-31 could be used, in the future, to control the symptoms and complications caused by septic-shock syndromes, in which patients’ survival depends largely on the control of the heavy-inflammatory status. Here, IL31 is linked to Sepsis.